Ral-lying around Ras

Most efforts to inhibit Ras have focused on its downstream MEK- or phosphoinositide 3-kinase-mediated pathways because blocking Ras directly is complicated by the lack of drug-binding pockets on the enzyme. A University of Colorado Denver-led team has now targeted a third Ras pathway-mediated by Ral GTPases-by developing Ral inhibitors and showing they reduce tumors in mice.¹

The compounds have been licensed by the NantBioscience subsidiary of NantWorks LLC...